Das Herz und die Psyche

S. Albinni; J. Hauser; D. Luckner; M. Marx

doi:10.1055/s-0038-1629318

Kinder- und Jugendmedizin, Table of Contents

Kinder- und Jugendmedizin 2013; 13(01): 28-36
DOI: 10.1055/s-0038-1629318

Kardiologie

Schattauer GmbH

Das Herz und die Psyche

Interaktionen im klinischen AlltagThe association between heart and mind Clinical links and aspects

S. Albinni

¹Klinische Abteilung für Pädiatrische Kardiologie, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien

,

J. Hauser

¹Klinische Abteilung für Pädiatrische Kardiologie, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien

,

D. Luckner

¹Klinische Abteilung für Pädiatrische Kardiologie, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien

,

M. Marx

¹Klinische Abteilung für Pädiatrische Kardiologie, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien

› Author Affiliations

Abstract

Zusammenfassung

Im Vergleich zur Normalbevölkerung haben Patienten mit psychiatrischen Erkrankungen eine höhere kardiale Mortalität. Einerseits besteht ein direkter kausaler Zusammenhang über hormonelle und hämatologische Prozesse, andererseits ist das erhöhte kardiovaskuläre Risiko zu einem Großteil auch auf die vermehrte Anwendung von psychotropen Substanzen zurückzuführen. Je nach Substanzgruppe beeinflussen Psychotropika in unterschiedlichem Ausmaß Repolarisation und Depolarisation sowie Blutdruck und Herzfrequenzverhalten. Der QTc-Verlängerung kommt dabei der größte Stellenwert zu, wobei sich die klinische Relevanz meist durch das Zusammenspiel unterschiedlicher Risikofaktoren ergibt. Diese und die unterschiedlichen Nebenwirkungsprofile von Psychopharmaka sowie Empfehlungen zum klinischen Vorgehen werden im nachfolgenden Beitrag überblicksmäßig erläutert.

Daneben wird dem Leser der Link zwischen Herz und Psyche anhand einzelner psychiatrischer Krankheitsbilder, die speziell Kinder und Jugendliche betreffen, näher gebracht.

Summary

In contrast to normal population, there is higher cardiac mortality in psychiatric patients. On the one hand there is evidence of haematological and hormonal abnormalities in psychiatric disorders responsible for increased cardiovascular risk, on the other hand the use of psychotropic drugs has been associated with increased cardiac death. Cardiac side effects depend on substance group and include changes of depolarisation, repolarisation as well as alterations in heart rate and blood pressure. Among these, prolongation of QTc interval is the most important, its clinical significance however is mostly linked to coexistence of one or more risk factors. The extent of cardiac side effects related to the use of antipsychotic agents, the impact of proven risk factors and clinical approach are discussed in this article.

Moreover the link between heart and psyche is illustrated by various psychiatric disorders affecting especially children and adolescents.

Schlüsselwörter

Psychopharmaka - kardiovaskuläres Risiko - psychiatrische Erkrankung

Keywords

Psychotropic - cardiovascular risk - mental disorder

Full Text

References

Literatur
1 Shah SU, White A, White S, Littler WA. Heart and mind: (1) relationship between cardiovascular and psychiatric conditions. Postgrad Med J 2004; 80: 683-689. Review
2 Anda R, Williamson D, Jones D. et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993; 4: 285-294.
3 Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-1980.
4 Scheier MF, Matthews KA, Owens JF. et al. Optimism and rehospitalization after coronary artery bypass surgery. Arch Intern Med 1999; 159: 829-835.
5 Aromaa A, Raitasalo R, Reunanen A. et al. Depression and cardiovascular diseases. Acta Psychiatr Scand 1994; 377 (Suppl) 77-82.
6 Ford DE, Mead LA, Chang PP. et al. Depression is a risk factor for coronary artery disease in men. Arch Intern Med 1996; 158: 1422-1426.
7 Hippisley-Cox J, Fielding K, Pringle M. Depression as a risk factor for ischemic heart disease in men: population based case-control study. BMJ 1998; 316: 1714-1719.
8 Wassertheil-Smoller S, Applegate WB, Berge K. et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the Elderly). Arch Intern Med 1996; 56: 553-561.
9 Frasure-Smith N, Lespe'rance F, Talajic M. Depression following myocardial infarction: Impact on 6-month survival. JAMA 1993; 270: 1819-1825.
10 Lespérance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996; 58: 99-110.
11 Dunbar SB, Kimble LP, Jenkins LS. et al. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress Anxiety 1999; 9: 163-168.
12 Carney RM, Rich MW, Tevelde A. et al. Major depressive disorder in coronary artery disease. Am J Cardiol 1987; 60: 1273-1275.
13 Mastrogiannis D, Giamouzis G, Dardiotis E. et al. Depression in patients with cardiovascular disease. Cardiol Res Pract 2012 2012; 794762.
14 Frasure-Smith N, Lespérance F, Habra M. et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009; 120: 134-140.
15 Diez-Quevedo C, Lupón J, González B. et al. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol 2012. Apr 14
16 Frasure-Smith N, Lesperance F, Talajic M. Depression and 18 month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
17 Carney RM, Freedland KE, Eisen S. et al. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995; 14: 88-90.
18 Carney R, Freedland K, Miller G. et al. Depression as a risk factor for cardiac mortality and morbidity. A review of potential mechanisms J Psychosom Res 2002; 53: 897-902.
19 Jiang W, Kuchibhatla M, Clary GL. et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007; 154: 102-108.
20 Suarez EC, Kuhn CM, Schanberg SM. et al. Neuroendocrine, cardiovascular, and emotional responses of hostile men: the role of interpersonal challenge. Psychosom Med 1998; 60: 78-88.
21 Wyatt RJ, Portnoy B, Kupfer DJ. et al. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 1971; 24: 65-70.
22 Roy A, Pickar D, DeJong J. et al. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine: relationship to hypothalamic- pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988; 45: 849-857.
23 Smagin GN, Heinrichs SC, Dunn AJ. The role of CRH in behavioral responses to stress. Peptides 2001; 22: 713-724.
24 Troxler RG, Sprague EA, Albanese RA. et al. The association of elevated plasma cortisol and early atherosclerosis as demonstrated by coronary angiography. Atherosclerosis 1977; 26: 151-162.
25 Sheilds RW. Functional anatomy of the autonomic nervous system. J Clin Neurophysiol 1993; 10: 2-13.
26 Follick MJ, Ahern DK, Gorkin L. et al. Relation of psychosocial and stress reactivity variables to ventricular arrhythmias in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990; 66: 63-67.
27 Miyawaki E, Salzman C. Autonomic nervous system tests in psychiatry: implications and potential uses of heart rate variability. Integrated Psychiatry 1991; 7: 21-28.
28 Carney RM, Saunders RD, Freeland KE. et al. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562-564.
29 Spyer KM. Central nervous system control of the cardiovascular system. In: Bannister R. (ed). Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. Oxford, UK: Oxford University Press; 1988: 56-79.
30 DeClerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 (Suppl. 05) S1-S5.
31 Biegon A, Weizman A, Karp L. et al. Serotonin 5-HT2 receptor binding on blood platelets: a peripheral marker for depression?. Life Sci 1987; 41: 2485-2492.
32 Pandy GN, Pandey PG, Janicak PG. Platelet serotonin-2 binding sites indepression and suicide. Biol Psychiatry 1990; 28: 215-222.
33 Laghirissi-Thode F, Wagner WR, Pollock BG. et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischaemic heart disease. Biol Psychiatry 1997; 42: 290-295.
34 Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298: 1794-1796.
35 Manu P, Kane JM, Correll CU. Sudden death in psychiatric patients. J Clin Psychiatry 2011; 72: 936-941.
36 Ray WA, Chung CP, Murray KT. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235.
37 Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58-77. Review
38 Bonnemeier H. Nichtinvasive Evaluation des potentiellen Rhythmuspatienten, Bedeutung von dynamischen QT-Intervall-Analysen. Herzschr Elektrophys 2007; 18: 30-38.
39 Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003 Fall 74: 291-306. Review
40 Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation 2010; 122: 1426-1435. Review
41 Moss AJ, Schwartz PJ, Crampton RS. et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-1144.
42 Zareba W, Moss AJ, le Cessie S. Risk of cardiac events in family members of patients with long QT syndrome. Journal of the American College of Cardiology 1995; 26: 1685-1691.
43 Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010; 5: 97-104.
44 Van Noord C, Straus S, Sturkenboom M. et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacology 2009; 29: 9-15.
45 Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 2002; 3: 479-479.
46 Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108: 687-693.
47 Astrom-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety 2008; 17: 587-592.
48 Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008; 4: 101-105.
49 Harrigan EP, Miceli JJ, Anziano R. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacology 2004; 24: 62-69.
50 Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacology 2005; 20: 243-251.
51 Reilly JG, Ayes SA, Ferrier IN. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 335: 1048-1052.
52 FDA. Information for Healthcare Professionals: Haloperidol. FDA ALERT 9/2007
53 Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005; 44: 73-79.
54 Christoph U, Correll JD, Lops VF. et al. QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone. J Clin Psychiatry 2011; 72: 854-860.
55 Gurovich I, Vempaty A, Lippmann S. QTc prolongation: chlorpromazine and high-dosage olanzapine. Can J Psychiatry 2003; 48: 348.
56 Dineen S, Withrow K, Voronovitch L. et al. QTc prolongation and high-dose olanzapine. Psychosomatics 2003; 44: 174-175.
57 Lange-Asschenfeldt C. Psychopharmakotherapie bei kardialen Erkrankungen. Journal für Kardiologie - Austrian Journal of Cardiology 2010; 17: 300-306.
58 Timour Q, Frassati D, Descotes J. et al. Sudden death of cardiac origin and psychotropic drugs. Front Pharmacol 2012; 3: 76.
59 Roose SP, Glassman AH, Dalack GW. Depression, heart disease, andricyclic antidepressants. J Clin Psychiatry 1989; 50 (Suppl) 12-16.
60 Lo Vecchio F, Hamilton RJ, Hoffman RJ. Risperidone overdose. Am J Emerg Med 1996; 14: 95-96.
61 Glassman AH, Roose SP, Bigger Jr JT. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993; 269: 2673-2675.
62 Kilian JG, Kerr K, Lawrence C, Celermajer D. S. Myocarditis and cardiomyopathy associ ated with clozapine. Lancet 1999; 354: 1841-1845.
63 Schulte P F. Reaction on myocarditis and cardiomyopathy underestimated complications resulting from clozapine therapy. Tijdschr Psychiatr 2011; 53: 193-194.
64 Belhani D, Frassati D, Mégard R. et al. Cardiac lesions induced by neuroleptic drugs in the rabbit. Exp Toxicol Pathol 2006; 57: 207-212.
65 Veselinoviæ T, Himmerich H. Antihistaminerge Antipsychotika verursachen Gewichtszunahme. Antihistaminergic antipsychotics cause weight gain. Der Nervenarzt 2010; 81: 329-334.
66 Neumärker KJ. Mortality and sudden death in anorexia nervosa. Int J Eat Disord 1997; 21: 205-212. Review
67 Krantz MJ, Sabel AL, Sagar U. et al. Factors influencing QT prolongation in patients hospitalized with severe anorexia nervosa. Gen Hosp Psychiatry 2012; 34: 173-177.
68 Koschke M, Boettger MK, Macholdt C. et al. Increased QT variability in patients with anorexia nervosa - an indicator for increased cardiac mortality? Department of Psychiatry and Psychotherapy. Int J Eat Disord 2010; 43: 743-750.
69 Isager T, Brinch M, Kreiner S, Tolstrup K. Death and relapse in anorexia nervosa: survival analysis of 151 cases. J Psychiatr Res 1985; 19: 515-521.
70 Isner JM, Roberts WC, Heymsfield SB, Yager J. Anorexia nervosa and sudden death. Ann Intern Med 1985; 102: 49-52.
71 Vanderdonckt O, Lambert M, Montero MC. et al. The 12-lead electrocardiogram in anorexia nervosa: A report of 2 cases followed by a retrospective study. J Electrocardiol 2001; 34: 233-242.
72 Swenne I, Larsson PT. Heart risk associated with weight loss in anorexia nervosa and eating disorders: risk factors for QTc interval prolongation and dispersion. Acta Paediatr 1999; 88: 304-309.
73 Durakovic Z, Durakovic A, Korsic M. Changes of the corrected QTinterval in the electrocardiogram of patients with anorexia nervosa. Int J Cardiol 1994; 45: 115-120.
74 Cooke RA, Chamber JB, Todd GJ. et al. QT interval in anorexia nervosa. Br Heart J 1994; 72: 69-73.
75 Lesinskiene S, Barkus A, Ranceva N, Dembinskas A. A meta-analysis of heart rate and QT interval alteration in anorexia nervosa. World J Biol Psychiatry 2008; 9: 86-89.
76 Facchini M, Sala L, Malfatto G. et al. Low-K + dependent QT prolongation and risk for ventricular arrhythmia in anorexia nervosa. Int J Cardiol 2006; 106: 170-176.
77 Olivares JL, Vázquez M, Fleta J. et al. Cardiac findings in adolescents with anorexia nervosa at diagnosis and after weight restoration. Eur J Pediatr 2005; 164: 383-386.
78 Mont L, Castro J, Herreros B. et al. Reversibility of cardiac abnormalities in adolescents with anorexia nerovsa after weight recovery. J Am Acad Child Adolesc Psychiatry 2003; 42: 808-813.
79 Lund K, Perkiomaki JS, Brohet C. et al. The prognostic accuracy of different QT interval measures. Ann Noninvasive Electrocardiol 2002; 7: 10-16.
80 Bonnemeier H, Wiegand UK, Giannitsis E. et al. Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Impact of admission troponin T. Am Heart J 2003; 145: 484-492.
81 Vrtovec B, Starc V, Starc R. Beat-to-beat QT interval variability in coronary patients. J Electrocardiol 2000; 33: 119-125.
82 Berger RD, Kasper EK, Baughman KL. et al. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997; 96: 1557-1565.
83 Roche F, Barthélémy JC, Mayaud N. et al. Refeeding normalizes the QT rate dependence of female anorexic patients. Am J Cardiol 2005; 95: 277-280.
84 Bonnemeier H. Clinical significance of dynamic QT-interval-analyses. Herzschrittmacherther Elektrophysiol 2007; 18: 30-38.
85 N. N. Heart risk associated with weight loss in anorexia nervosa and eating disorders: electrocardiographic changes during the early phase of refeeding. Swenne I Acta Paediatr 2000; 89: 447-452.
86 Tresley J, Sheean PM. Refeeding Syndrome: Recognition Is the Key to Prevention and Management. J Am Diet Assoc 2008; 108: 2105-2108.
87 Mazurak N, Enck P, Muth E. et al. Heart rate variability as a measure of cardiac autonomic function in anorexia nervosa: A review of the literature. Eur Eat Disord Rev 2010; (2010/12), ISSN 1099-0968.
88 Katzman DK. Medical complications in adolescents with anorexia nervosa: a review of the literature. Int J Eat Disord 2005; 37: S52-S59.
89 Kastner S, Salbach-Andrae H, Renneberg B. et al. Echocardiographic findings in adolescents with anorexia nervosa at beginning of treatment and after weight recovery Eur Child Adolesc Psychiatry. 2012; 21: 15-21.
90 Upadhyaya HP. Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician. Prim Care Companion J Clin Psychiatry 2008; 10: 211-221.
91 Habel LA, Cooper WO, Sox CM. et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306: 2673-2683.
92 Winterstein AG. Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use. Evid Based Ment Health 2012; 15: 43.
93 Eric Mick David D, McManus Robert J. Goldberg. Meta-analysis of increased heartrate and blood pressure associated with CNS stimulant reatmentof ADHD in adults. European Neuropsychopharmacology(2012) http://dx.doi.org/
94 10.1016/j. euroneuro.2012.06.011
95 Hamilton RM, Rosenthal E, HulpkeWette M. et al. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder GuidelinesGroup on attention deficit hyperactivity disorder drug safety meeting. Cardiology in the Young 2012; 22: 63-70.
96 Prasad A. Apical ballooning syndrome: an important differential diagnosis of acute myocardial infarction. Circulation 2007; 115: e56-9.
97 Wittstein IS, Thiemann DR, Lima JA. et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352: 539-548.
98 Nykamp D, Titak JA. Takotsubo Cardiomyopathy, or Broken-Heart Syndrome. Ann Pharmacother 2010; 44: 590-593.
99 Lee SY, Lee SE, Choi JW. et al. A case of transient left ventricular apical ballooning syndrome in a child: clinical features and imaging findings. Int J Cardiovasc Imaging 2010; 26: 345-351.
100 Biteker M, Duran NE, Civan HA. Broken heart syndrome in a 17-year-old girl. Eur J Pediatr 2009; 168: 1273-1275.
101 Schoof S, Bertram H, Hohmann D. et al. Takotsubo Cardiomyopathy in a 2-Year-Old Girl. 3-Dimensional Visualization of Reversible Left Ventricular Dysfunction. Journal of the American College of Cardiology 2010; 55: 309-316.
102 Ahn JH, Park SH, Shin WY. et al. Long QT syndrome and torsade de pointes associated with Takotsubo cardiomyopathy. J Korean Med Sci 2011; 26: 959-961.
103 Ghosh S, Apte P, Maroz N. et al. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes. Int J Cardiol 2009; 136: 225-227.
104 Madias C, Fitzgibbons TP, Alsheikh-Ali AA. et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm 2011; 8: 555.
105 Gordon M. Memorandum from the Division of Cardio Renal Drug Products Consultation (www.fda.gov/ohrms/dockets)